AstraTrace — For Health Authorities & Regulators
Continuously updated pharmaceutical supply chain visibility — without asking manufacturers to build bespoke reporting for you.
The AstraTrace Regulator Portal gives health authorities direct, controlled access to the supply chain data layer. Manufacturer data. Updated continuously. No charge. The Alberta Health pilot is live today.
Request a conversation
We respond within one business day.
The problem health authorities face
You need pharmaceutical supply chain visibility. Manufacturers need governance they can trust before sharing data.
- 01Shortage signals reach health authorities too late — because they depend on manufacturer self-reporting. Most health authority shortage intelligence comes from manufacturer voluntary notifications — after the manufacturer has identified the shortage internally. The downstream visibility that health authorities need to detect shortages independently, before manufacturers report them, requires access to supply chain data that manufacturers do not share with individual health authorities bilaterally.
- 02Bilateral data-sharing arrangements with manufacturers are operationally unsustainable at scale. A health authority negotiating individual data-sharing agreements with each of 20 major manufacturers, each with different data formats, different API architectures, and different legal review timelines, cannot build a functioning continuously updated supply chain visibility capability. The bilateral model does not scale.
- 03Manufacturers will share supply chain data with a neutral infrastructure operator they cannot share with a single health authority. The governance model matters. A proprietary vendor controlled by commercial interests creates hesitancy. A Swiss nonprofit, with no data monetisation and pharmaceutical industry board oversight, creates the trust conditions for data sharing that individual bilateral arrangements cannot.
The Regulator Portal
Direct access to the supply chain data layer. No charge. No bilateral negotiation required.
The AstraTrace Regulator Portal gives authorised health authorities direct, controlled access to the supply chain data of manufacturers who have connected to the AstraTrace network. Access is governed by PLA as the neutral infrastructure operator — not negotiated bilaterally between health authorities and individual manufacturers.
Network-level visibility
Access to supply chain data from all manufacturers connected to the AstraTrace network — not just those with whom you have a bilateral data-sharing arrangement. As more manufacturers connect, the health authority's visibility compounds.
Continuously updated, not retrospective
EPCIS events ingested continuously as manufacturers sync data. Stock positions, movement events, batch locations, and cold chain status available as they are generated — not as weekly or monthly reports compiled by manufacturer teams.
Controlled access — governed by PLA
Access permissions are managed by PLA under the network governance rules. Manufacturers retain control over which data categories are visible through the Regulator Portal. Health authorities access only the data categories covered by the network governance framework.
The Alberta Health model
What network-level supply chain intelligence looks like in a live provincial health system.
Alberta Health Services operates centralised pharmaceutical purchasing and distribution across the province — one of the few health systems globally with the structural conditions to demonstrate network-level supply chain intelligence in a live environment.
The Alberta Health pilot connects manufacturer EPCIS supply chain events and provincial health authority operational data on the same AstraTrace infrastructure. The result: shortage signals become visible at the network level — upstream manufacturer supply positions and downstream provincial distribution patterns in the same view, updated with every data sync.
What Alberta Health can see
Continuously updated manufacturer supply positions for products in the Alberta provincial system. Batch-level inventory locations across the distribution chain. Cold chain status for temperature-sensitive products. Early shortage signal detection before formal manufacturer notification.
What manufacturers can see
Provincial distribution patterns and stock levels downstream of their own tier. Point-of-dispense consumption patterns (where available). The health authority's operational demand signals — enabling better supply forecasting without requiring direct bilateral communication with the authority.
Shortage detection use case
What early-warning shortage intelligence looks like in practice.
A shortage signal forms when the pattern of downstream stock depletion diverges from normal replenishment timelines. In a standard manufacturer-reporting model, this divergence becomes visible to the health authority only when the manufacturer reports it — typically after the shortage has already formed at the distribution level.
In the AstraTrace network model, the divergence is detectable in the data layer before the manufacturer has assembled its own internal picture. The health authority's Regulator Portal shows the downstream consumption pattern changing. The manufacturer's AstraTrace dashboard shows the same upstream supply position. Both parties see the signal simultaneously — enabling a coordinated response before the shortage reaches patients.
"The governance model is what makes data sharing possible. Manufacturers share data with a neutral nonprofit infrastructure that they would not share with a single health authority's proprietary system. That is not a commercial argument — it is a structural reality."
Why the nonprofit governance model matters for health authorities
No commercial interest. No data monetisation. Board oversight from the industry you regulate.
PharmaLedger Association is a Swiss nonprofit with no commercial interest in the data flowing through the AstraTrace network. Fees from manufacturers fund the infrastructure. There is no advertising model, no data licensing, and no investor return obligation that could create pressure to monetise health authority or manufacturer supply chain data.
The Board of Directors includes representatives from GSK, MSD, and Takeda — manufacturers who have assessed the governance model and concluded it provides adequate data sovereignty protection for their supply chain data. Health authorities operating the Regulator Portal participate in the same governance framework.
Also for your role
Common questions
Frequently asked questions
Is the Regulator Portal genuinely at no charge?
Which manufacturers are currently connected to the AstraTrace network?
What data can manufacturers see about health authority operations through the network?
How does a health authority join the AstraTrace network?
How does AstraTrace handle data sovereignty requirements for health authority data?
The Alberta Health pilot is live. The Regulator Portal is available now — at no charge.
Request a 30-minute Regulator Portal briefing. We walk through the Alberta Health model, the data access framework, and what onboarding looks like for your organisation specifically.
Request a Regulator Portal briefing